AGT-1
Latest Information Update: 04 Nov 2003
At a glance
- Originator Advanced Biotherapy
- Developer Advanced Biotherapy; Brown University Medical School; GroupMed CRO; Russian Academy of Medical Sciences; Russian State Medical University
- Class Antibodies
- Mechanism of Action Immunosuppressants; Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Multiple sclerosis in Russia (unspecified route)
- 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in Russia (Injection)
- 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Systemic lupus erythematosus in Russia (IM)